| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.25B | — | +16.2% |
| Cost of Revenue | $5.89B | — | +11.9% |
| R&D Expense | $959.7M | — | +16.6% |
| SG&A Expense | $602.6M | — | +43.0% |
| Operating Income | $3.96B | — | +18.2% |
| Pre-tax Income | $6.55B | — | +103.7% |
| Income Tax | $1.26B | — | +291.0% |
| Net Income | $5.28B | — | +82.8% |
| EPS (Basic) | $1.25 | — | -81.5% |
| EPS (Diluted) | $1.23 | — | -81.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $12.26B | +35.7% | +70.3% |
| Short-term Investments | $28.7M | +0.0% | -97.6% |
| Current Assets | $17.07B | +31.1% | +45.9% |
| Total Assets | $61.02B | +9.7% | +17.1% |
| Current Liabilities | $12.13B | +10.5% | +24.8% |
| Long-term Debt | $13.36B |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $5.29B | — | +89.7% |
| Capital Expenditures | $196.1M | — | +52.9% |
| Investing Cash Flow | -$781.9M | — | -261.0% |
| Financing Cash Flow | -$1.23B | — | +69.4% |
| Free Cash Flow | $5.09B | — | +91.4% |
| -4.6% |
| Total Liabilities | $29.89B | +3.1% | +6.5% |
| Stockholders' Equity | $31.13B | +16.9% | +29.5% |